Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations : a meta-analysis
Aim: This study aims to clarify toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations. Methods: Eligible studies included randomized studies evaluating chemotherapy with or without an immune checkpoint inhibitor (including pembrolizumab, nivolumab, atezolizumab, durvalumab or avelumab). The primary summary statistic was the relative risk (RR). Results: A total of 11 studies were finally included into this meta-analysis. RRs of high-grade anemia, thrombocytopenia and neutropenia were 0.98 (95% CI: 0.83-1.16; p = 0.84), 1.10 (95% CI: 0.83-1.47; p = 0.51) and 0.96 (0.78-1.17; p = 0.66), respectively. RR of high-grade nausea, vomiting and diarrhea was 1.19 (95% CI: 0.78-1.82; p = 0.42), 1.09 (95% CI: 0.69-1.72; p = 0.71) and 2.61 (1.42-4.79; p = 0.002), respectively. Conclusion: Addition of immune checkpoint inhibitors to chemotherapy backbone does not increase the risk of high-grade hematological or gastrointestinal toxicities (except for high-grade diarrhea).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Immunotherapy - 11(2019), 6 vom: 01. Apr., Seite 543-554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdel-Rahman, Omar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse events |
|---|
| Anmerkungen: |
Date Completed 06.03.2020 Date Revised 06.03.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2217/imt-2018-0186 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297532847 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297532847 | ||
| 003 | DE-627 | ||
| 005 | 20231225092209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2018-0186 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0991.xml |
| 035 | |a (DE-627)NLM297532847 | ||
| 035 | |a (NLM)31135244 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdel-Rahman, Omar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations |b a meta-analysis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2020 | ||
| 500 | |a Date Revised 06.03.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This study aims to clarify toxicity patterns associated with chemotherapy/immune checkpoint inhibitor combinations. Methods: Eligible studies included randomized studies evaluating chemotherapy with or without an immune checkpoint inhibitor (including pembrolizumab, nivolumab, atezolizumab, durvalumab or avelumab). The primary summary statistic was the relative risk (RR). Results: A total of 11 studies were finally included into this meta-analysis. RRs of high-grade anemia, thrombocytopenia and neutropenia were 0.98 (95% CI: 0.83-1.16; p = 0.84), 1.10 (95% CI: 0.83-1.47; p = 0.51) and 0.96 (0.78-1.17; p = 0.66), respectively. RR of high-grade nausea, vomiting and diarrhea was 1.19 (95% CI: 0.78-1.82; p = 0.42), 1.09 (95% CI: 0.69-1.72; p = 0.71) and 2.61 (1.42-4.79; p = 0.002), respectively. Conclusion: Addition of immune checkpoint inhibitors to chemotherapy backbone does not increase the risk of high-grade hematological or gastrointestinal toxicities (except for high-grade diarrhea) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a adverse events | |
| 650 | 4 | |a atezolizumab | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a pembrolizumab | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Costimulatory and Inhibitory T-Cell Receptors |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d 2009 |g 11(2019), 6 vom: 01. Apr., Seite 543-554 |w (DE-627)NLM19257163X |x 1750-7448 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:6 |g day:01 |g month:04 |g pages:543-554 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2018-0186 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 6 |b 01 |c 04 |h 543-554 | ||